Brazilian Journal of TRANSPLANTATION

https://doi.org/10.53855/bjt.v28i1.668_ENG

REVIEW ARTICLE

Bioprinting in Organ Transplantation: From Experimental Models to Clinical Prospects

Kirolos Eskandar[1,*]

1.Helwan University – Faculty of Medicine and Surgery – Cairo – Egypt.

*Corresponding author: kiroloss.eskandar@gmail.com

Seccion editor: Ilka de Fátima Santana F. Boin

Received: Feb. 3, 2025 | Approved: Mar. 14, 2025

ABSTRACT

Background: Bioprinting has emerged as an innovative technology in organ transplantation and regenerative medicine, aiming to address pressing challenges such as the shortage of donor organs and the need for effective tissue repair. By leveraging advanced 3D printing techniques, bioprinting enables the fabrication of functional tissues and organs with precise architectural and biological properties. **Methods:** This review provides an in-depth analysis of the latest advancements in bioprinting, focusing on cutting-edge techniques, the development of bioinks, and their applications in tissue engineering. It examines significant breakthroughs in the creation of vascularized and transplantable organ prototypes and explores the role of bioprinting in personalized medicine. **Results:** The findings highlight the transformative impact of bioprinting in the biomedical field, particularly in drug testing, therapeutic modeling, and patient-specific treatment strategies. Additionally, key challenges—including technological limitations, ethical concerns, and regulatory considerations—are discussed to provide a comprehensive understanding of the field's progress and potential obstacles. **Conclusion:** Bioprinting holds immense promise for revolutionizing global healthcare by offering solutions for organ shortages and advancing regenerative medicine. However, continued research and innovation are necessary to overcome existing challenges and facilitate its clinical translation into mainstream medical practice.

Descriptors: Tissue Engineering; 3D Printing Technologies; Graft Viability; Biomedical Innovation; Implantable Constructs.

Bioimpressão no Transplante de Órgãos: Dos modelos Experimentais às Perspectivas Clínicas

RESUMO

Introdução: A bioimpressão despontou como uma tecnologia inovadora no transplante de órgãos e na medicina regenerativa, visando solucionar desafios urgentes, como a escassez de órgãos de doadores e a necessidade de reparo eficaz de tecidos. Ao aproveitar as técnicas avançadas de impressão 3D, a bioimpressão permite a fabricação de tecidos e órgãos funcionais com propriedades arquitetônicas e biológicas precisas. **Métodos:** Esta revisão fornece uma análise detalhada dos últimos avanços em bioimpressão, concentrando-se em técnicas de ponta, no desenvolvimento de biotintas e em suas aplicações na engenharia de tecidos. Ela examina os avanços significativos na criação de protótipos de órgãos vascularizados e transplantáveis e explora a função da bioimpressão na medicina personalizada. **Resultados:** As descobertas destacam o impacto transformador da bioimpressão no campo biomédico, particularmente em testes de medicamentos, modelagem terapêutica e estratégias de tratamento específicas para o paciente. Além disso, os principais desafios — incluindo limitações tecnológicas, preocupações éticas e considerações regulatórias — são discutidos para fornecer uma compreensão abrangente do progresso do campo e dos possíveis obstáculos. **Conclusão:** A bioimpressão é imensamente promissora para revolucionar a saúde global, oferecendo soluções para a escassez de órgãos e o avanço da medicina regenerativa. No entanto a pesquisa e a inovação contínuas são necessárias para superar os desafios existentes e facilitar sua tradução clínica para a prática médica convencional.

Descritores: Engenharia de Tecidos; Tecnologias de Impressão 3D; Viabilidade do Enxerto; Inovação Biomédica; Construções Implantáveis.

INTRODUCTION

Bioprinting is an innovative subset of 3D printing that involves the layer-by-layer deposition of living cells and biomaterials to create structures that mimic the complexity of natural tissues and organs. This technology utilizes bioinks—composed of cells, growth factors, and biocompatible materials—to fabricate constructs with precise architectural and functional properties. The process is meticulously controlled to ensure the viability and correct placement of cells, facilitating the development of tissue constructs that can integrate seamlessly with the human body.[1]

Bioprinting employs various techniques to achieve precise tissue fabrication. Extrusion-based bioprinting utilizes a continuous flow of bioink extruded through a nozzle, making it ideal for printing large tissue structures with high cell density. Inkjet-based bioprinting, on the other hand, employs thermal or acoustic forces to eject small droplets of bioink, enabling high-resolution patterning of cells and biomaterials. Laser-assisted bioprinting uses focused laser beams to deposit bioinks with exceptional precision, making it particularly useful for creating intricate tissue architectures[2]. Each method has distinct advantages and is selected based on the specific requirements of the tissue being fabricated.

The origins of bioprinting are deeply rooted in the evolution of 3D printing technologies. In 1984, Charles Hull introduced stereolithography, a technique that laid the foundation for 3D printing by enabling the creation of objects through the sequential layering of materials. This method initially found applications in engineering and manufacturing. By the late 1990s, advancements in material science led to the development of biocompatible materials suitable for medical applications, paving the way for the emergence of bioprinting[2]. A significant milestone was achieved in 1999 when Dr. Anthony Atala and his team at the Wake Forest Institute for Regenerative Medicine successfully printed a scaffold for a human bladder, which was then seeded with the patient's own cells to create a functional organ[3]. This breakthrough demonstrated the potential of bioprinting in regenerative medicine. Subsequent developments included the printing of miniature functional kidneys in 2002 and the patenting of inkjet bioprinting techniques by Dr. Thomas Boland in 2003, which utilized modified printers to deposit cells into organized 3D matrices[4]. These foundational achievements have propelled bioprinting from a conceptual framework to a burgeoning field with significant clinical implications.

The importance of bioprinting in addressing organ shortages cannot be overstated. Traditional organ transplantation faces significant challenges, including a limited supply of donor organs and the risk of immune rejection. Bioprinting offers a promising solution by enabling the fabrication of patient-specific organs using their own cells, thereby reducing the likelihood of rejection, and eliminating the dependence on donor availability[5]. This approach not only has the potential to save countless lives but also to revolutionize the field of regenerative medicine by providing customized therapeutic options tailored to individual patient needs. As research progresses, bioprinting is poised to become a cornerstone technology in the development of functional tissues and organs, addressing the critical demand for transplants and advancing personalized medicine.

METHODOLOGY

A scoping review approach was employed to conduct this literature review, ensuring a broad and comprehensive analysis of the field. Below, we provide a detailed breakdown of the methodology, including the search strategy, inclusion/exclusion criteria, screening process, and quality assessment.

Search strategy

A comprehensive search was conducted in four major academic databases—PubMed, Google Scholar, Scopus, and Web of Science—to identify relevant articles and studies on bioprinting. The search focused on the following keywords and Boolean combinations to maximize coverage: "Bioprinting," "3D Bioprinting," "Organ Transplantation," "Regenerative Medicine," "Personalized Medicine," "Bioinks," "Vascularization in Bioprinting."

Synonyms and related terms were included in the search strategy to ensure a wide-ranging retrieval of literature. The search was restricted to peer-reviewed articles published in English between 2018 and 2025. The search strategy was designed to capture the breadth and depth of the field, including technological, biological, and clinical advancements in bioprinting.

Inclusion and exclusion criteria

The following inclusion and exclusion criteria were applied to select relevant studies for this review:

Inclusion criteria

1. Publications in peer-reviewed journals;
2. Studies focusing specifically on bioprinting technologies and applications;

3. Articles addressing advancements in 3D organ bioprinting, personalized medicine, and regenerative therapies;
4. Papers reporting experimental, computational, or clinical advancements in bioprinting.

Exclusion criteria

1. Studies published in languages other than English;
2. Non-peer-reviewed articles, conference proceedings, and abstracts;
3. Articles lacking experimental validation, such as opinion pieces and theoretical models without practical implementation;
4. Studies that did not focus on organ bioprinting or lacked relevance to clinical applications.

Screening and selection process

The initial search yielded a total of 141 articles. The selection process consisted of three phases:

Phase 1: Removal of duplicates using reference management software: All retrieved articles were screened for duplicate entries. After this step, 83 unique articles remained.

Phase 2: Title and abstract screening: The titles and abstracts of the remaining articles were independently reviewed. Studies that clearly did not meet the inclusion criteria based on the abstract were excluded. This step resulted in the retention of 62 articles.

Phase 3: Full-text screening: The full texts of the remaining 62 articles were assessed for relevance and quality. Articles were excluded if they lacked robust data, detailed methodology, or alignment with the objectives of this review. After this rigorous assessment, 48 articles were selected for inclusion in the final review.

Data extraction

A standardized data extraction form was developed to capture key information from each study, including: author(s) and publication year; study design and methodology; key findings and conclusions; relevance to bioprinting in organ transplantation and regenerative medicine.

Data extraction was performed independently to ensure accuracy and consistency.

Quality assessment

The quality of the included studies was assessed using Risk of Bias in Systematic Reviews (ROBIS) and Cochrane risk-of-bias tools, ensuring methodological rigor. Experimental studies were evaluated for reproducibility, statistical analyses, and controls, while computational and simulation-based studies were assessed for validation metrics. Clinical studies were reviewed for ethical compliance, sample size, and translational relevance.

Limitations of the methodology

While this scoping review ensures a broad coverage of the field, some limitations are acknowledged. First, restricting the search to English-language publications may have excluded relevant studies in other languages. Second, the reliance on peer-reviewed literature may have overlooked emerging but unpublished findings in the field. Finally, the dynamic nature of bioprinting advancements necessitates ongoing updates to this review as new studies become available.

PRISMA flow diagram

To enhance transparency, a PRISMA flow diagram (Fig. 1) is included to illustrate the stepwise process of study selection. The diagram details the number of records identified, screened, excluded, and included at each stage, along with reasons for exclusions.



Source: Elaborated by the author.

Figure 1. PRISMA flow diagram.

RESULTS

Significant advancements in bioprinting technology have been achieved, particularly in the development of vascularized organ structures, enhanced bioinks, and improved precision in cell placement. Innovations such as multimaterial bioprinting and AI-assisted design have contributed to greater print fidelity and functionality, allowing for more complex tissue architectures and improved survival rates of printed cells. These technological breakthroughs mark a crucial step toward the clinical translation of bioprinting by enhancing the structural and functional integrity of bioprinted constructs.

In terms of clinical applications, bioprinting has demonstrated considerable potential in drug testing, wound healing, and tissue regeneration. Bioprinted tissues are now being used as models for pharmaceutical research, providing more accurate platforms for evaluating drug efficacy and toxicity while reducing the reliance on animal testing. Additionally, bioprinted skin grafts have shown success in wound healing by accelerating tissue regeneration and improving integration with surrounding tissues. While fully functional bioprinted organs are not yet available for transplantation, progress has been made in printing liver and cardiac tissues, with preclinical models demonstrating promising functional properties. These advancements indicate that bioprinting may eventually lead to personalized organ transplants tailored to individual patient needs.

Despite these promising developments, ethical and regulatory challenges remain significant barriers to the widespread adoption of bioprinting. Ethical concerns include issues of patient consent, bioink sourcing, and the use of genetically modified materials, which raise questions regarding donor rights and long-term safety. Regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) continue to refine policies governing bioprinted medical products, requiring extensive validation to ensure their safety and efficacy before approval for human use. Moreover, accessibility concerns must be addressed to prevent bioprinting from exacerbating healthcare disparities, ensuring that its benefits reach diverse patient populations rather than remaining restricted to well-funded institutions.

Technologies and techniques in bioprinting

Bioprinting encompasses a range of sophisticated techniques designed to fabricate complex, functional biological structures. Among the primary methods are extrusion-based bioprinting, inkjet bioprinting, and stereolithography. Extrusion-based bioprinting involves the continuous deposition of bioink through a nozzle, allowing for the creation of intricate, cell-laden constructs with high cell density[6]. This method is particularly advantageous for producing larger tissue structures due to its ability to print with a variety of viscosities and materials. Inkjet bioprinting, on the other hand, utilizes thermal or acoustic forces to eject droplets of bioink onto a substrate, enabling high-resolution patterning of cells and biomaterials. This technique is noted for its speed and precision, making it suitable for applications requiring detailed cellular arrangements. Stereolithography employs light to selectively cure photosensitive bioinks, facilitating the construction of structures with exceptional resolution and complexity[7]. This approach is particularly useful for fabricating scaffolds with precise architectural features.

Central to the success of these bioprinting techniques is the selection of appropriate bioinks, which are formulations composed of living cells and biomaterials that mimic the extracellular matrix environment. Bioinks must possess properties that support cell viability, proliferation, and differentiation, while also providing the mechanical integrity necessary for the printed structure[8]. Common bioink components include natural polymers such as alginate, gelatin, and hyaluronic acid, which offer biocompatibility and promote cellular functions. Synthetic polymers like polyethylene glycol are also utilized to enhance mechanical properties and tailor degradation rates[9]. The choice of bioink is critical, as it influences the printability, structural stability, and biological performance of the bioprinted construct.

The integration of scaffolds and cellular matrices in bioprinting is essential for replicating the complex architecture of native tissues. Scaffolds provide a three-dimensional framework that supports cell attachment and guides tissue development. In some bioprinting approaches, synthetic materials are printed to form molds or rigid layers that contain the bioink, preventing it from spreading and maintaining the desired shape of the construct[10]. These scaffolds can be designed to degrade over time, allowing the developing tissue to replace the scaffold material as it matures. The combination of scaffolds with cell-laden bioinks enables the fabrication of tissue constructs that closely mimic the structural and functional properties of natural tissues, advancing the field of regenerative medicine.[11]

Recent innovations and breakthroughs

Recent advancements in bioprinting have significantly propelled the field toward the fabrication of functional tissues and organs, addressing critical challenges in regenerative medicine. Innovations in bioprinting techniques have enabled the creation of complex tissue architectures that closely mimic their natural counterparts[12]. For instance, researchers have developed methods to bioprint thick adipose tissues with integrated vascular networks, enhancing the viability and functionality of the constructs. These developments are pivotal in overcoming previous limitations related to tissue thickness and nutrient diffusion.[13]

Notable progress has been made in the bioprinting of organ prototypes such as the kidney, liver, and heart. In 2024, a study demonstrated the bioprinting of liver tissues with complex vascular architectures, which exhibited essential liver functions and responsiveness to drug treatments[14]. Similarly, advancements in cardiac tissue engineering have led to the successful bioprinting of heart tissues that demonstrate synchronized contractions and electrophysiological properties akin to native heart tissue[15]. These prototypes represent significant milestones toward the development of fully functional bioprinted organs for transplantation.

A critical aspect of bioprinting functional tissues is the incorporation of vascular networks to ensure adequate nutrient and oxygen supply. Recent studies have focused on the synergistic coupling between 3D bioprinting and vascularization strategies to enhance tissue viability. For example, researchers have explored the use of growth factor gradients and coculture systems to promote the formation of hierarchical vascular networks within bioprinted tissues[16]. Additionally, computational modeling approaches have been employed to design organ-scale synthetic vasculature, facilitating the biomanufacturing of larger and more complex tissue constructs. These efforts are crucial in addressing the challenges associated with vascularization in bioprinted tissues, thereby bringing the field closer to the realization of transplantable bioprinted organs.[17]

Applications in regenerative medicine

Bioprinting has emerged as a transformative approach in regenerative medicine, offering innovative solutions for tissue engineering and wound healing. By precisely depositing cells and biomaterials, bioprinting enables the creation of complex tissue constructs that closely mimic native tissues. This technology facilitates the development of customized grafts tailored to patient-specific needs, thereby enhancing the efficacy of treatments for various injuries and degenerative conditions.[18]

In the realm of bone and cartilage regeneration, bioprinting has demonstrated significant potential. By utilizing bioinks composed of cells and supportive biomaterials, researchers have successfully fabricated constructs that promote the regeneration of bone and cartilage tissues[19]. These bioprinted structures provide a conducive environment for cell proliferation and differentiation, leading to the restoration of function in damaged skeletal tissues. This approach holds promise for addressing challenges associated with bone defects and cartilage injuries, offering a pathway to improved patient outcomes.[20]

Skin bioprinting represents a significant advancement in the treatment of burn injuries. Traditional skin grafting methods often face limitations such as donor site morbidity and limited availability of healthy tissue. Bioprinting offers a promising alternative by enabling the fabrication of skin constructs that can be customized to the patient's wound geometry[21]. This approach not only accelerates the healing process but also improves the aesthetic and functional outcomes for burn victims. Recent studies have highlighted the potential of bioprinted skin substitutes in promoting wound healing and reducing scar formation, thereby enhancing the quality of life for patients with severe burns.[22,23]

Bioprinting for organ transplantation

Bioprinting holds significant promise for organ transplantation, yet several challenges impede the creation of fully functional, transplantable organs. One primary obstacle is replicating the intricate vascular networks essential for nutrient delivery and waste removal in thick tissues. Achieving the necessary cellular density and spatial organization to mimic native tissue functionality remains complex[23]. Additionally, ensuring the mechanical integrity and long-term viability of bioprinted organs poses substantial difficulties. The selection of suitable bioinks that support cell proliferation and differentiation while maintaining printability and structural stability is critical. Moreover, the integration of bioprinted constructs with the host's biological systems, including immune compatibility and the establishment of functional interfaces with existing tissues, presents further challenges.[24]

Despite these hurdles, notable research milestones have been achieved in the field of bioprinting for organ transplantation. For instance, researchers have successfully bioprinted liver tissue constructs that exhibit key liver functions, such as albumin production and cytochrome P450 enzyme activity, indicating potential for drug testing and disease modeling applications[25]. In cardiac tissue engineering, advancements have led to the bioprinting of heart tissues demonstrating synchronized contractions and electrophysiological properties similar to native myocardium. These developments represent significant steps toward the realization of bioprinted organs suitable for transplantation.[26]

A compelling advantage of bioprinting is its potential to mitigate organ rejection. By utilizing a patient's own cells to create bioinks, bioprinted organs can be customized to the individual's unique genetic and immunological profile, thereby reducing the risk of immune rejection[27]. This personalized approach not only enhances biocompatibility but also eliminates the need for immunosuppressive therapies, which are associated with adverse side effects and increased susceptibility to infections.

Traditional organ transplantation relies on donor organs, which are often in limited supply, leading to long waiting lists and high mortality rates among patients awaiting transplants. Bioprinting, on the other hand, has the potential to generate organs on demand, addressing the shortage issue. However, while bioprinted tissues have demonstrated promising functional properties in preclinical studies, achieving full organ functionality comparable to donor organs remains a challenge.[28]

Although bioprinting eliminates costs associated with organ procurement and transplantation-related logistics, it introduces expenses related to specialized equipment, bioink development, and the high costs of ensuring regulatory compliance. Advances in automation and scalable production techniques will be crucial in reducing these costs over time.

The path to clinical translation for bioprinted organs involves rigorous validation through preclinical and clinical trials. Regulatory agencies such as the FDA and EMA require extensive safety and efficacy data before approving bioprinted organs for human transplantation. Currently, bioprinted tissues have primarily been used in drug testing and disease modeling, with only a few cases reaching early-stage clinical applications. Overcoming regulatory hurdles will be essential for bioprinting to become a mainstream alternative to traditional organ transplantation.

Role in personalized medicine

Bioprinting has emerged as a pivotal technology in personalized medicine, enabling the customization of tissues and organs to meet patient-specific requirements. By utilizing a patient's own cells, bioprinting facilitates the creation of bespoke tissue constructs that align with individual anatomical and physiological characteristics, thereby enhancing the efficacy of therapeutic interventions[29]. This approach not only improves treatment outcomes but also minimizes the risk of immune rejection, as the bioprinted tissues are inherently compatible with the patient's immune system.

In the realm of drug testing and disease modeling, bioprinting offers significant advancements. Traditional drug testing methodologies often rely on animal models, which may not accurately replicate human physiological responses, leading to potential discrepancies in drug efficacy and toxicity profiles[30]. Bioprinted human tissue models provide a more accurate platform for evaluating drug responses, thereby reducing the reliance on animal testing and enhancing the predictive validity of preclinical studies[31]. Moreover, these bioprinted models can be tailored to represent specific disease states, allowing for more precise investigations into disease mechanisms and the development of targeted therapies.

The implementation of patient-specific bioprinting also raises important ethical considerations. Issues such as the sourcing of cells, consent for their use, and the long-term implications of creating bioprinted tissues warrant careful deliberation[32]. Additionally, the potential for bioprinting to exacerbate healthcare disparities, particularly if access to such advanced treatments is limited to certain populations, must be addressed. Regulatory frameworks need to evolve to ensure the ethical application of bioprinting technologies, balancing innovation with patient safety and equitable access.[33]

Challenges and limitations

Bioprinting, while promising, faces several technological and biological challenges that hinder its progression toward clinical application. A significant issue is scalability; fabricating human-scale tissues and organs necessitates prolonged printing durations, during which maintaining cell viability becomes challenging[34]. Prolonged exposure to environmental stressors during extended print times can compromise cell health, leading to reduced functionality of the bioprinted tissue.[35]

Additionally, the complexity of engineering tissues with intricate structures poses substantial hurdles. Achieving the necessary cellular density and spatial organization to mimic native tissue functionality remains complex. Ensuring the mechanical integrity and long-term viability of bioprinted organs poses substantial difficulties[36]. The selection of suitable bioinks that support cell proliferation and differentiation while maintaining printability and structural stability is critical. Moreover, the integration of bioprinted constructs with the host's biological systems, including immune compatibility and the establishment of functional interfaces with existing tissues, presents further challenges.[37]

While clinical translation remains in its early stages, bioprinted tissues are already being utilized in pharmaceutical research for drug testing, reducing the reliance on animal models. Additionally, the development of bioprinted skin grafts for burn victims has shown promising clinical applications. These early successes provide a glimpse into the broader potential of bioprinting once scalability and regulatory challenges are addressed.

Regulatory and clinical trial challenges further complicate the advancement of bioprinting technologies. The multifaceted nature of bioprinted products, which combine aspects of 3D printing, cell therapy, and custom implants, presents a unique challenge to existing regulatory frameworks[38]. Current regulations may not adequately address the complexities inherent in bioprinted tissues, necessitating the development of new guidelines to ensure safety and efficacy.

Cost and accessibility also pose significant barriers to the widespread adoption of bioprinting technologies. The high costs associated with bioprinting equipment, materials, and specialized personnel limit accessibility, particularly in resource-constrained settings[39]. This economic barrier could exacerbate existing healthcare disparities, restricting the benefits of bioprinting advancements to well-funded institutions and populations. Addressing these cost and accessibility issues is crucial for the equitable implementation of bioprinting in clinical practice.[32]

Ethical, legal, and social implications

The emergence of bioprinting technology, particularly in the fabrication of human tissues and organs, presents a complex array of ethical, legal, and social implications that warrant thorough examination.

Ethically, the creation of human tissues and organs through bioprinting raises questions about the moral boundaries of scientific intervention in natural biological processes. While this technology holds the promise of alleviating organ shortages, it also prompts concerns regarding the commodification of human life and the potential for creating entities that challenge our definitions of personhood[40]. Furthermore, the use of human cells in bioprinting necessitates careful consideration of donor consent and the ethical sourcing of biological materials.[41]

Legally, bioprinting intersects with complex intellectual property issues. Determining the patentability of bioprinted materials is challenging, as traditional patent systems often exclude products derived from natural phenomena. This ambiguity complicates the protection of innovations in bioprinting and may hinder the field's advancement[42]. Additionally, the classification of bioprinted organs under existing legal frameworks remains unresolved. For instance, if bioprinted organs are deemed equivalent to natural human organs, they may fall under regulations such as the National Organ Transplant Act, which prohibits the sale of human organs, thereby impacting the commercialization of bioprinted products.[32]

Socially, bioprinting has the potential to significantly impact global healthcare equity. The high costs associated with bioprinting technologies could limit access to advanced treatments, particularly in low-resource settings, thereby exacerbating existing health disparities[33]. Moreover, the ability to produce human tissues and organs may lead to societal debates regarding the definition of life and the moral status of bioprinted entities. These discussions necessitate inclusive public engagement to navigate the societal implications of bioprinting responsibly.[43]

FUTURE DIRECTIONS

The field of bioprinting is poised for significant advancements, driven by emerging trends such as the integration of artificial intelligence (AI) and robotics. The convergence of AI with bioprinting enables the analysis of complex biological data, facilitating the design of more precise and functional tissue constructs[44]. AI algorithms can optimize printing parameters in real-time, enhancing the fidelity and efficiency of the bioprinting process. Additionally, the incorporation of robotic systems, particularly robotic arm-based 3D bioprinting, offers improved automation and precision, allowing for the fabrication of complex tissue structures with high spatial accuracy.[45]

Interdisciplinary collaboration plays a pivotal role in advancing bioprinting technologies. The fusion of expertise from fields such as biology, engineering, materials science, and computer science fosters innovation and addresses multifaceted challenges inherent in bioprinting[46]. This collaborative approach, often referred to as bioconvergence, leverages diverse methodologies to solve complex problems in regenerative medicine and beyond.

Looking ahead, the next decade in bioprinting and regenerative medicine is expected to witness transformative developments. Advancements in AI and robotics are anticipated to further refine bioprinting techniques, enabling the production of more complex and functional tissues and organs[47]. Moreover, the ongoing integration of interdisciplinary approaches is likely to yield innovative solutions to current limitations, such as vascularization and tissue maturation. These developments hold the promise of bringing bioprinting closer to clinical applications, potentially revolutionizing personalized medicine and addressing the global shortage of transplantable organs.[48]

CONCLUSION

Bioprinting has emerged as a groundbreaking technology with immense potential to revolutionize medicine, addressing critical challenges in organ transplantation, regenerative therapies, and personalized medicine. This literature review has explored the foundational principles, technological advancements, and applications of bioprinting, while shedding light on the ethical, legal, and societal implications. The integration of cutting-edge technologies, such as artificial intelligence and robotics, alongside interdisciplinary collaboration, is paving the way for transformative breakthroughs in the field. Although challenges such as scalability, vascularization, regulatory hurdles, and equitable access remain significant, ongoing research and innovation continue to push the boundaries of what is possible. By envisioning a future where bioprinted tissues and organs become widely available, this field holds the promise to bridge gaps in global healthcare, offering hope for improved patient outcomes and a new era in regenerative medicine.

CONFLICT OF INTEREST

The author declares that they have no competing interests.

DECLARATION ON THE USE OF GENERATIVE ARTIFICIAL INTELLIGENCE

The author declares that he did not use AI tools in writing the text and assumes full responsibility for the content of the publication.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

FUNDING

Not applicable.

ACKNOWLEDGEMENT

Not applicable.

REFERENCES

1. Persaud A, Maus A, Strait L, Zhu D. 3D Bioprinting with Live Cells. Eng Regen 2022;3(3):292-309. https://doi.org/10.1016/j.engreg.2022.07.002
2. Gu Z, Fu J, Lin H, He Y. Development of 3D bioprinting: From printing methods to biomedical applications. Asian J Pharm Sci 2019;15(5):529-57. https://doi.org/10.1016/j.ajps.2019.11.003
3. Atala A, Bauer SB, Soker S, Yoo JJ, Retik AB. Tissue-engineered autologous bladders for patients needing cystoplasty. Lancet 2006;367(9518):1241-6. https://doi.org/10.1016/S0140-6736(06)68438-9
4. Mierke CT. Bioprinting of cells, organoids and organs-on-a-chip together with hydrogels improves structural and mechanical cues. Cells 2024;13(19):1638. https://doi.org/10.3390/cells13191638
5. Jongh D, Massey EK, Cronin AJ, Schermer MHN, Bunnik EM, VANGUARD Consortium. Early-phase clinical trials of bio-artificial organ technology: A systematic review of ethical issues. Transpl Int 2022;35:10751. https://doi.org/10.3389/ti.2022.10751
6. Fang Y, Guo Y, Liu T, Xu R, Mao S, Mo X, et al. Advances in 3D bioprinting. Chin J Mech Eng 2022;1(1):100011. https://doi.org/10.1016/j.cjmeam.2022.100011
7. Budharaju H, Sundaramurthi D, Sethuraman S. Embedded 3D bioprinting – An emerging strategy to fabricate biomimetic & large vascularized tissue constructs. Bioact Mater 2023;32:356-84. https://doi.org/10.1016/j.bioactmat.2023.10.012
8. Chen X, Anvari-Yazdi AF, Duan X, Zimmerling A, Gharraei R, Sharma N, et al. Biomaterials / bioinks and extrusion bioprinting. Bioactive Materials 2023;28:511-36. https://doi.org/10.1016/j.bioactmat.2023.06.006
9. Brahme P, Rarokar N, Kumbhalkar R, Saoji S, Khedekar P. Natural and synthetic polymeric hydrogel: a bioink for 3D bioprinting of tissue models. J Drug Deliv Sci Technol 2024(Part A);106204. https://doi.org/10.1016/j.jddst.2024.106204
10. Do AV, Khorsand B, Geary SM, Salem AK. 3D Printing of Scaffolds for Tissue Regeneration Applications. Adv Healthc Mater 2015;4(12):1742-62. https://doi.org/10.1002/adhm.201500168
11. Selim M, Mousa HM, Abdel-Jaber G, Barhoum A, Abdal-Hay A. Innovative designs of 3D scaffolds for bone tissue regeneration: Understanding principles and addressing challenges. Eur Polym J 2024;215:113251. https://doi.org/10.1016/j.eurpolymj.2024.113251
12. Mirshafiei M, Rashedi H, Yazdian F, Rahdar A, Baino F. Advancements in tissue and organ 3D bioprinting: Current techniques, applications, and future perspectives. Mater Des 2024;240:112853. https://doi.org/10.1016/j.matdes.2024.112853
13. Datta P, Ayan B, Ozbolat IT. Bioprinting for vascular and vascularized tissue biofabrication. Acta Biomater 2017;51:1-20. https://doi.org/10.1016/j.actbio.2017.01.035
14. Wang X, Zhang D, Singh YP, Yeo M, Deng G, Lai J, et al. progress in organ bioprinting for regenerative medicine. Engineering 2024;42:121-42. https://doi.org/10.1016/j.eng.2024.04.023

15. Cui H, Miao S, Esworthy T, Zhou X, Lee SJ, Liu C, et al. 3D bioprinting for cardiovascular regeneration and pharmacology. Adv Drug Deliv Rev 2018;132:252-69. https://doi.org/10.1016/j.addr.2018.07.014

16. Yeo M, Sarkar A, Singh YP, Derman ID, Datta P, Ozbolat IT. Synergistic coupling between 3D bioprinting and vascularization strategies. Biofabrication 2023;16(1):012003. https://doi.org/10.1088/1758-5090/ad0b3f

17. Sexton ZA, Hudson AR, Herrmann JE, Shiwarski DJ, Pham J, Szafron JM, et al. Rapid model-guided design of organ-scale synthetic vasculature for biomanufacturing. ArXiv 2023;arXiv:2308.07586v1. https://doi.org/10.48550/arXiv.2308.07586

18. Tripathi S, Mandal SS, Bauri S, Maiti P. 3D bioprinting and its innovative approach for biomedical applications. MedComm 2022;4(1):e194. https://doi.org/10.1002/mco2.194

19. Chiticaru EA, Ioniță M. Commercially available bioinks and state-of-the-art lab-made formulations for bone tissue engineering: a comprehensive review. Mater Today Bio 2024;29:101341. https://doi.org/10.1016/j.mtbio.2024.101341

20. Zhou J, Li Q, Tian Z, Yao Q, Zhang M. Recent advances in 3D bioprinted cartilage-mimicking constructs for applications in tissue engineering. Mater Today Bio 2023;23:100870. https://doi.org/10.1016/j.mtbio.2023.100870

21. Varkey M, Visscher DO, van Zuijlen PPM, Atala A, Yoo JJ. Skin bioprinting: the future of burn wound reconstruction? Burns Trauma 2019;7:4. https://doi.org/10.1186/s41038-019-0142-7

22. Kolimi P, Narala S, Nyavanandi D, Youssef AAA, Dudhipala N. Innovative treatment strategies to accelerate wound healing: trajectory and recent advancements. Cells 2022;11(15):2439. https://doi.org/10.3390/cells11152439

23. Huang G, Zhao Y, Chen D, Wei L, Hu Z, Li J, et al. Applications, advancements, and challenges of 3D bioprinting in organ transplantation. Biomater Sci 2024;12(6):1425-44. https://doi.org/10.1039/d3bm01934a

24. Mathur V, Agarwal P, Kasturi M, Srinivasan V, Seetharam RN, Vasanthan KS. Innovative bioinks for 3D bioprinting: Exploring technological potential and regulatory challenges. J Tissue Eng 2025;16:1-31. https://doi.org/10.1177/20417314241308022

25. Mota C, Camarero-Espinosa S, Baker MB, Wieringa P, Moroni L. Bioprinting: from tissue and organ development to in vitro models. Chem Rev 2020;120(19):10547-607. https://doi.org/10.1021/acs.chemrev.9b00789

26. Wang Z, Wang L, Li T, Liu S, Guo B, Huang W, Wu Y. 3D bioprinting in cardiac tissue engineering. Theranostics 2021;11(16):7948-69. https://doi.org/10.7150/thno.61621

27. Yaneva A, Shopova D, Bakova D, Mihaylova A, Kasnakova P, Hristozova M, et al. The progress in bioprinting and its potential impact on health-related quality of life. Bioengineering 2023;10(8):910. https://doi.org/10.3390/bioengineering10080910

28. Shopova D, Yaneva A, Bakova D, Mihaylova A, Kasnakova P, Hristozova M, et al. (Bio)printing in personalized medicine-opportunities and potential benefits. Bioengineering 2023;10(3):287. https://doi.org/10.3390/bioengineering10030287

29. Lam EHY, Yu F, Zhu S, Wang Z. 3D bioprinting for next-generation personalized medicine. Int J Mol Sci 2023;24(7):6357. https://doi.org/10.3390/ijms24076357

30. Parihar A, Parihar DS, Gaur K, Arya N, Choubey VK, Khan R. 3D bioprinting for drug development and screening: recent trends towards personalized medicine. Hybrid Adv 2024;100320. https://doi.org/10.1016/j.hybadv.2024.100320

31. Yang K, Wang L, Vijayavenkataraman S, Yuan Y, Tan E, Kang L. Recent applications of three-dimensional bioprinting in drug discovery and development. Adv Drug Deliv Rev 2024;115456. https://doi.org/10.1016/j.addr.2024.115456

32. Ricci G, Gibelli F, Sirignano A. Three-dimensional bioprinting of human organs and tissues: bioethical and medico-legal implications examined through a scoping review. Bioengineering 2023;10(9):1052. https://doi.org/10.3390/bioengineering10091052

33. Kantaros A, Ganetsos T, Petrescu FIT, Alysandratou E. Bioprinting and intellectual property: challenges, opportunities, and the road ahead. Bioengineering 2025;12(1):76. https://doi.org/10.3390/bioengineering12010076

34. Vijayavenkataraman S. 3D bioprinting: challenges in commercialization and clinical translation. J 3D Print Med 2023;7(2):3DP8. https://doi.org/10.2217/3dp-2022-0026

35. Xu HQ, Liu JC, Zhang ZY, Xu CX. A review on cell damage, viability, and functionality during 3D bioprinting. Mil Med Res 2022;9(1):70. https://doi.org/10.1186/s40779-022-00429-5

36. Derman ID, Moses JC, Rivera T, Ozbolat IT. Understanding the cellular dynamics, engineering perspectives and translation prospects in bioprinting epithelial tissues. Bioact Mater 2024;43:195-224. https://doi.org/10.1016/j.bioactmat.2024.09.025

37. Hasan MM, Ahmad A, Akter MZ, Choi YJ, Yi HG. Bioinks for bioprinting using plant-derived biomaterials. Biofabrication 2024;16(4):042004. https://doi.org/10.1088/1758-5090/ad6932

38. Mladenovska T, Choong PF, Wallace GG, O'Connell CD. The regulatory challenge of 3D bioprinting. Regen Med 2023;18(8):659-74. https://doi.org/10.2217/rme-2022-0194

39. Tong A, Pham QL, Abatemarco P, Mathew A, Gupta D, Iyer S, et al. Review of low-cost 3D bioprinters: state of the market and observed future trends. SLAS Technol 2021;26(4):333-66. https://doi.org/10.1177/24726303211020297

40. Kirillova A, Bushev S, Abubakirov A, Sukikh G. Bioethical and legal issues in 3D bioprinting. Int J Bioprint 2020;6(3):272. https://doi.org/10.18063/ijb.v6i3.272

41. Gilbert F, O'Connell CD, Mladenovska T, Dodds S. Print me an organ? Ethical and regulatory issues emerging from 3D bioprinting in medicine. Sci Eng Ethics 2017;24(1):73–91. https://doi.org/10.1007/s11948-017-9874-6

42. Devarapalli P, Ajay D. The impact of 3D bioprinting innovation on IP ecosystem and patent law: an Indian and US perspective. In: Singh K, Chongtham N, Trikha R, Bhardwaj M, Kaur S, editors. Science, technology and innovation ecosystem: an Indian and global perspective. 2024. p. 197-210. https://doi.org/10.1007/978-981-97-2815-2_9

43. Vijayavenkataraman S, Lu W, Fuh J. 3D bioprinting – an ethical, legal and social aspects (ELSA) framework. Bioprinting 2016;1-2:11–21. https://doi.org/10.1016/j.bprint.2016.08.001

44. Zhang Z, Zhou X, Fang Y, Xiong Z, Zhang T. AI-driven 3D bioprinting for regenerative medicine: from bench to bedside. Bioact Mater 2024;45:201-30. https://doi.org/10.1016/j.bioactmat.2024.11.021

45. Barjuei ES, Shin J, Kim K, Lee J. Precision improvement of robotic bioprinting via vision-based tool path compensation. Sci Rep 2024;14:17764. https://doi.org/10.1038/s41598-024-68597-z

46. Aljohani W, Ullah MW, Zhang X, Yang G. Bioprinting and its applications in tissue engineering and regenerative medicine. Int J Biol Macromol 2017;107:261-75. https://doi.org/10.1016/j.ijbiomac.2017.08.171

47. Jain P, Kathuria H, Dubey N. Advances in 3D bioprinting of tissues/organs for regenerative medicine and in-vitro models. Biomaterials 2022;287:121639. https://doi.org/10.1016/j.biomaterials.2022.121639

48. Jovic TH, Combellack EJ, Jessop ZM, Whitaker IS. 3D bioprinting and the future of surgery. Front Surg 2020;7:609836. https://doi.org/10.3389/fsurg.2020.609836